MX2013006527A - Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos. - Google Patents

Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.

Info

Publication number
MX2013006527A
MX2013006527A MX2013006527A MX2013006527A MX2013006527A MX 2013006527 A MX2013006527 A MX 2013006527A MX 2013006527 A MX2013006527 A MX 2013006527A MX 2013006527 A MX2013006527 A MX 2013006527A MX 2013006527 A MX2013006527 A MX 2013006527A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
ophthalmologic disorders
arylsulfonamide derivatives
specific
Prior art date
Application number
MX2013006527A
Other languages
English (en)
Inventor
Pierre Belichard
Didier Pruneau
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of MX2013006527A publication Critical patent/MX2013006527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se dirige al uso terapéutico de los derivados de arilsulfonamida.
MX2013006527A 2010-12-09 2011-12-09 Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos. MX2013006527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306381 2010-12-09
PCT/EP2011/072306 WO2012076685A1 (en) 2010-12-09 2011-12-09 Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders

Publications (1)

Publication Number Publication Date
MX2013006527A true MX2013006527A (es) 2014-06-11

Family

ID=43567690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006527A MX2013006527A (es) 2010-12-09 2011-12-09 Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.

Country Status (15)

Country Link
US (1) US20130315903A1 (es)
EP (1) EP2648712B1 (es)
JP (1) JP2013544871A (es)
CN (1) CN103402507B (es)
AR (1) AR084194A1 (es)
AU (1) AU2011340494B2 (es)
BR (1) BR112013014379A2 (es)
CA (1) CA2820124A1 (es)
ES (1) ES2559223T3 (es)
HK (1) HK1186383A1 (es)
MX (1) MX2013006527A (es)
RU (1) RU2583929C2 (es)
UY (1) UY33788A (es)
WO (1) WO2012076685A1 (es)
ZA (1) ZA201304121B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125912A0 (en) * 1996-02-26 1999-04-11 Advanced Res & Tech Inst Use of carbonic anhydrase inhibitors for treating macular edema
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
RU2393824C1 (ru) * 2009-04-14 2010-07-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения макулярных отеков различного генеза
AR084193A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Dosificaciones de derivados de arilsufonamida

Also Published As

Publication number Publication date
CN103402507B (zh) 2016-02-17
HK1186383A1 (en) 2014-03-14
BR112013014379A2 (pt) 2016-09-27
RU2583929C2 (ru) 2016-05-10
EP2648712A1 (en) 2013-10-16
CA2820124A1 (en) 2012-06-14
US20130315903A1 (en) 2013-11-28
AR084194A1 (es) 2013-04-24
AU2011340494B2 (en) 2015-05-14
CN103402507A (zh) 2013-11-20
UY33788A (es) 2012-07-31
EP2648712B1 (en) 2015-10-21
JP2013544871A (ja) 2013-12-19
ZA201304121B (en) 2014-08-27
WO2012076685A1 (en) 2012-06-14
AU2011340494A1 (en) 2013-05-02
ES2559223T3 (es) 2016-02-11
RU2013131281A (ru) 2015-01-20

Similar Documents

Publication Publication Date Title
MX2014005304A (es) Biaril eter sulfonamidas y su uso como agentes terapeuticos.
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
IN2015DN01156A (es)
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
MY165579A (en) Synthetic methods for spiro-oxindole compounds
ZA201108305B (en) Novel p2x7r antagonists and their use
MX2014012266A (es) Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
IN2014CN03123A (es)
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
TH1401001121B (th) เก้าอี้ออร์โทพีดิกส์สำหรับการรักษาและการป้องกันโรคกระดูกสันหลัง
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.

Legal Events

Date Code Title Description
FG Grant or registration